Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis

Andrew J. Prendergast\textsuperscript{a,b}, Mutsa Bwakura-Dangarembizi\textsuperscript{c}, Peter Mugyenyi\textsuperscript{d}, Joseph Lutaakome\textsuperscript{e}, Adeodata Kekitiinwa\textsuperscript{f}, Margaret J. Thomason\textsuperscript{b}, Diana M. Gibb\textsuperscript{b}, A. Sarah Walker\textsuperscript{b}, on behalf of the ARROW Trial Team

**Objective:** To evaluate whether cotrimoxazole prophylaxis prevents common skin conditions in HIV-infected children.

**Design:** Open-label randomized controlled trial of continuing versus stopping daily cotrimoxazole (post-hoc analysis).

**Setting:** Three sites in Uganda and one in Zimbabwe.

**Participants:** A total of 758 children aged more than 3 years receiving antiretroviral therapy (ART) for more than 96 weeks in the ARROW trial were randomized to stop ($n=382$) or continue ($n=376$) cotrimoxazole after median (interquartile range) 2.1 (1.8, 2.2) years on ART.

**Intervention:** Continuing versus stopping daily cotrimoxazole.

**Main outcome measures:** Nurses screened for signs/symptoms at 6-week visits. This was a secondary analysis of ARROW trial data, with skin complaints categorized blind to randomization as bacterial, fungal, or viral infections; dermatitis; pruritic papular eruptions (PPEs); or others (blisters, desquamation, ulcers, and urticaria). Proportions ever reporting each skin complaint were compared across randomized groups using logistic regression.

**Results:** At randomization, median (interquartile range) age was 7 (4, 11) years and CD4$^+$ was 33\% (26, 39); 73\% had WHO stage 3/4 disease. Fewer children continuing cotrimoxazole reported bacterial skin infections over median 2 years follow-up (15 versus 33\%, respectively; $P<0.001$), with similar trends for PPE ($P=0.06$) and other skin complaints ($P=0.11$), but not for fungal ($P=0.45$) or viral ($P=0.23$) infections or dermatitis ($P=1.0$). Bacterial skin infections were also reported at significantly fewer clinic visits (1.2 versus 3.0\%, $P<0.001$). Independent of cotrimoxazole, bacterial skin infections were more common in children aged 6–8 years, with current CD4$^+$ cell count less than 500 cells/\mu l, WHO stage 3/4, less time on ART, and lower socio-economic status.
Conclusion: Long-term cotrimoxazole prophylaxis reduces common skin complaints, highlighting an additional benefit for long-term prophylaxis in sub-Saharan Africa.

Keywords: bacteria, children, cotrimoxazole, HIV, skin infections, sub-Saharan Africa

Introduction

Recurrent skin infections are common during childhood in developing countries [1,2], leading to frequent clinic attendances, risk of complications, and reduced quality of life [3]. In HIV-infected children, skin infections are more severe and atypical, respond less well to treatment, and relapse more frequently compared with HIV-uninfected children [4].

Cotrimoxazole prophylaxis reduces death and hospitalization from serious bacterial infections in HIV-infected children on antiretroviral therapy (ART) in sub-Saharan Africa [5], despite high rates of resistance among common bacterial isolates [6]. It is unclear whether long-term cotrimoxazole reduces common conditions such as skin infections, although its potential antimicrobial activity against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Streptococcus pyogenes suggests that prophylaxis may have benefits [7–10]. We therefore investigated the frequency of skin complaints among HIV-infected children enrolled in the ARROW trial in Zimbabwe and Uganda, who were randomized to stop or continue cotrimoxazole prophylaxis.

Methods

Of the 1206 children in the ARROW trial in Uganda/Zimbabwe, 758 meeting eligibility criteria were randomized to stop (n = 382) or continue (n = 376) daily cotrimoxazole (open-label) after median [interquartile range (IQR)] 2.1(1.8, 2.2) years on ART [5]. Eligible children were aged more than 3 years, had been receiving ART for more than 96 weeks, were currently on cotrimoxazole, using insecticide-treated bednets if living in malaria-endemic areas, and had no previous Pneumocystis jirovecii pneumonia. All children were followed to ARROW trial closure (16 March 2012). The coprimary endpoints were hospitalization or death and grade 3 or 4 adverse events, as previously reported [5]. Caregivers and older children (≥18 years) gave written consent; those aged 7–18 years gave assent depending on knowledge of their HIV status. The trial was approved by Research Ethics Committees in Uganda, Zimbabwe, and the UK.

The current post-hoc analysis compared skin complaints and other routinely solicited signs and symptoms between randomized groups. These were identified at 6-week visits, when nurses screened for 25 prespecified signs/symptoms using a standardized checklist (fever; weight loss; weakness/tiredness; pallor; jaundice/yellow eyes; rash; new bruises/masses/bumps; muscle aching/pain; abdominal aching/pain; poor appetite; difficulty feeding; sore mouth/throat/ulcers/thrush; vomiting/nausea; chronic, bloody, or moderate–severe diarrhoea; dehydration; cough; difficult/fast breathing; ear discharge/pain; difficulty walking; delayed developmental milestones; new visual problems; poor sleep/bad dreams; funny feeling/numbness/pain in hands or feet; depression/withdrawn; and severe headache) and also solicited any other symptoms. Skin complaints were reported as ‘other symptoms’ and categorized blind to randomization (by A.J.P.) by their clinical description, as bacterial (boils, abscesses, sores, impetigo, pustules, and infected wounds), fungal (tinea, ringworm, fungal infection, and scalp lesions) viral (varicella, warts, molluscum contagiosum, verrucae planae, herpes labialis, and herpes zoster), pruritic papular eruptions (PPEs), dermatitis (eczema, itching, or pruritus without PPE), or others (blisters, desquamation, ulcers, and urticaria); microbiological and histopathological data were not available. During 12-week examinations, doctors recorded any clinical findings. A socio-economic questionnaire was completed at trial enrolment and every 2 years subsequently; the closest questionnaire completed up to 60 days postcotrimoxazole randomization was used [517 (68%) within 1 year of randomization].

Proportions of children ever reporting each sign/symptom were compared across randomized groups using exact tests and logistic regression, and across visit weeks using generalized estimating equations (independent correlation structure), taking P less than 0.01 as the significance threshold, because these were not primary or secondary endpoints. Univariable associations between proportions reporting bacterial skin infections and demographic and clinical factors pre-ART and at randomization to stop versus continue cotrimoxazole were assessed using rank-sum and exact tests for continuous and categorical variables, respectively. A multivariable model for ever presenting with a bacterial infection was constructed using backwards elimination.
(exit \(P=0.1\) to fit an explanatory model) on all factors except household income/expenditure (missing for 30 children), allowing for nonlinearity in continuous factors using fractional polynomials. Interactions between randomized group and other factors were tested and retained when the interaction \(P\) was less than 0.1, and the additional impact of household income and expenditure was estimated. All analyses used Stata 14.0 StataCorp, College Station, Texas, USA.

Results

At randomization to stop versus continue cotrimoxazole, children were median (IQR) 7 (4, 11) years old and had spent 2.1 (1.8, 2.2) years on ART. Median CD4\(^+\) was 33\% (26, 39), compared with pre-ART CD4\(^+\) of 13\% (8, 18); 59 and 14\% children had WHO stages 3 and 4 disease, respectively (Supplementary Table 1, http://links.lww.com/QAD/A984). There was no difference in the prevalence of different skin complaints or other signs/symptoms at randomization (Supplementary Table 2, http://links.lww.com/QAD/A984). Children were followed for median (IQR) 108 (97, 117) weeks postrandomization and seen at a total of 12,747 scheduled nurse visits. Adherence to randomized cotrimoxazole strategy was high, as previously reported [5].

Fewer children continuing compared with stopping cotrimoxazole ever reported bacterial skin infections [56 (15\%) versus 125 (33\%), respectively; \(P<0.001\); Fig. 1a]. Effects were in a similar direction for PPE (\(P=0.06\)) and other skin complaints (\(P=0.11\)). There was no evidence of a difference in fungal (\(P=0.45\)) or viral (\(P=0.23\)) infections or dermatitis (\(P=1.00\)). Bacterial skin infections were also reported at significantly fewer nurse clinic visits between 6 and 120 weeks postrandomization in those continuing cotrimoxazole (1.2 versus 3.0\% stopping; \(P<0.001\); Fig. 1b), but there was no evidence of a difference between randomized groups in the proportion of clinic visits at which other skin complaints were reported (all \(P>0.15\)). Furthermore, fewer children continuing cotrimoxazole ever had clinically significant bacterial skin infections recorded by the doctor at examination [24 (6\%) versus 49 (13\%) stopping; \(P=0.003\)]; there were no differences between groups for nonbacterial skin complaints as recorded by clinicians (all \(P>0.15\)).

Seven of the 25 solicited signs/symptoms (fever, weight loss, tiredness/weakness, bruises, poor appetite, nausea, and cough) also occurred significantly less commonly in children continuing versus stopping cotrimoxazole (Supplementary Fig. 1A, http://links.lww.com/QAD/A983) and were reported at significantly fewer scheduled visits (Supplementary Fig. 1B, http://links.lww.com/QAD/A983). Effects were in a similar direction for rash, difficulty feeding, sore mouth, diarrhoea, and headache (0.04 < \(P<0.08\), Supplementary Fig. 1C and D, http://links.lww.com/QAD/A983). No sign/symptom was reported more frequently in children continuing cotrimoxazole.

Independent of cotrimoxazole, in a multivariable model bacterial skin infections were more common in children aged 6–8 years, with current CD4\(^+\) cell count less than 500 cells/\(\mu\)l, WHO stage 3/4, less time on ART at cotrimoxazole randomization, and with lower socioeconomic status as measured both by a household asset score and getting water from a well; and were less common in those receiving efavirenz (all \(P<0.05\); Table 1). Reductions in bacterial skin infections with cotrimoxazole ever reported bacterial skin infections [56 (15\%) versus 125 (33\%), respectively; \(P<0.001\); Fig. 1a]. Effects were in a similar direction for PPE (\(P=0.06\)) and other skin complaints (\(P=0.23\)). There was no evidence of a difference in bacterial skin infections or dermatitis (\(P=0.94\)) or viral (\(P=0.10\)) infections (Fig. 1b), but there was no evidence of a difference between randomized groups in the proportion of children who ever reported skin complaints at nurse visits during median 2 years of follow-up and (b) the proportion of scheduled nurse clinic visits in which skin complaints were reported. Grey bars show proportions among children randomized to continue cotrimoxazole and white bars show proportions among children randomized to stop cotrimoxazole after median 2.1 years of antiretroviral therapy. Percentages with the corresponding \(P\) value and odds ratios with 95\% confidence intervals are shown.
### Table 1. Characteristics at randomization to stop versus continue cotrimoxazole and impact on subsequent reported bacterial skin infections.

| Factor (at randomization to stop versus continue cotrimoxazole) | Without bacterial skin infection | With bacterial skin infection | Multivariable model<sup>a</sup> |
|---------------------------------------------------------------|---------------------------------|------------------------------|---------------------------------|
|                                                              | n (%) or median (IQR)           | n (%) or median (IQR)        | Odds ratio (95% confidence interval) | P (adjusted) |
| Age (years)                                                   | 8 (4, 11)                       | 7 (4, 9)                     | 4 year: 0.36 (0.18, 0.72)       | 0.004 |
|                                                              |                                 |                              | 7 year: 1.00 –                  |       |
|                                                              |                                 |                              | 10 year: 0.37 (0.22, 0.60)     | <0.001 |
|                                                              |                                 |                              | 13 year: 0.20 (0.09, 0.42)     | <0.001 |
|                                                              |                                 |                              | 15 year: 0.17 (0.02, 0.51)     |       |
|                                                              |                                 |                              | 17 year: 0.03 (0.00, 0.21)     |       |
|                                                              |                                 |                              | 19 year: 0.01 (0.00, 0.07)     |       |
|                                                              |                                 |                              | 21 year: 0.00 (0.00, 0.04)     |       |
|                                                              |                                 |                              | 23 year: 0.00 (0.00, 0.02)     |       |
|                                                              |                                 |                              | 25 year: 0.00 (0.00, 0.01)     |       |
|                                                              |                                 |                              | 27 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 29 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 31 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 33 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 35 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 37 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 39 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 41 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 43 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 45 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 47 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 49 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 51 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 53 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 55 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 57 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 59 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 61 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 63 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 65 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 67 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 69 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 71 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 73 year: 0.00 (0.00, 0.00)     |       |
|                                                              |                                 |                              | 75 year: 0.00 (0.00, 0.00)     |       |
| Randomized to                                                 |                                 |                              |                                 |       |
| Stop cotrimoxazole                                            | 257 (67%)                       | 125 (33%)                    | 1.00 –                           |       |
| Continue cotrimoxazole                                       | 320 (85%)                       | 56 (15%)                     | 0.26 (0.15, 0.46)                | <0.001 |
| <500 cells/µl and continue cotrimoxazole                     |                                 |                              | 0.09 (0.03, 0.29)               |       |
| 3TC ABC EFV<sup>b</sup> and continue cotrimoxazole           |                                 |                              | 1.00 –                           |       |
| ZDV 3TC ABC and continue cotrimoxazole                       |                                 |                              | 0.86 (0.38, 1.98)               | Heterogeneity P = 0.02 |
| CD4<sup>c</sup>                                               |                                 |                              | 0.34 (0.17, 0.68)               | Heterogeneity P = 0.57 |
| <500 cells/µl                                                | 105 (72%)                       | 40 (28%)                     | 2.69 (1.46, 4.97)                | 0.002 |
| ≥500 cells/µl                                                | 472 (77%)                       | 141 (23%)                    | 1.00 –                           |       |
| ART                                                          | 173 (83%)                       | 35 (17%)                     | 0.26 (0.14, 0.49)                | <0.001 |
| 3TC ABC EFV<sup>b</sup>                                      | 212 (71%)                       | 86 (29%)                     | 2.00 (1.08, 2.86)                | 0.02  |
| ZDV 3TC ABC                                                  | 192 (76%)                       | 60 (24%)                     | 0.53 (0.27, 1.02)                | 0.06  |
| Years on ART (Per year longer)                               | 2.1 (1.8, 2.3)                  | 2.1 (1.8, 2.3)               | 1.00 –                           |       |
| WHO stage (worst)                                            | 1 or 2                          | 169 (83%)                    | 1.00 –                           |       |
|                                                              | 3 or 4                          | 408 (72%)                    | 1.00 –                           |       |
|                                                              | Domestic tap                     | 350 (79%)                    | 93 (21%)                        | 1.00  |
|                                                              | Standpipe                       | 97 (78%)                     | 27 (22%)                        | 1.14  |
|                                                              | Well                            | 128 (68%)                    | 61 (32%)                        | 1.76  |
|                                                              | Household asset score<sup>c</sup> | –0.7 (–0.9, –1.1)            | –0.9 (–1.3, –0.0)               | 0.88  |
|                                                              |                                  |                                |                                  | 0.04  |

<sup>a</sup>See Supplementary Table 1, http://links.lww.com/QAD/A984 for all characteristics considered. P > 0.25 for all other factors in Supplementary Table 1, http://links.lww.com/QAD/A984.

<sup>b</sup>Including four children on lopinavir/ritonavir containing second-line therapy, none of whom developed a bacterial skin infection.

<sup>c</sup>Calculated as the first principal component of nine household items (refrigerator, radio, television, video player, landline telephone, mobile phone, motorbike, bicycle and car).

<sup>d</sup>At reference category; receiving 3TC ABC NVP at cotrimoxazole randomization with CD4<sup>c</sup> cell count at least 500 cells/µl.

3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; EFV, efavirenz; NVP, nevirapine; ZDV, zidovudine.
than 500 cells/μl (heterogeneity/interaction \( P = 0.06 \)) and smaller in those on efavirenz (heterogeneity/interaction \( P = 0.02 \)). In the 726 children with household income/expenditure data, risk of bacterial skin infections was independently lower in those spending a greater percentage of their household income on school (odds ratio per 5% points higher 0.97 (95% confidence interval 0.95–1.00), \( P = 0.03 \); effects of other factors similar to Table 1).

Discussion

HIV-infected children continuing long-term cotrimoxazole in Uganda and Zimbabwe had fewer bacterial skin infections than children stopping cotrimoxazole, despite good immune reconstitution on ART. There was also a marginal reduction in PPEs and a significant reduction in other important signs/symptoms such as cough, fever, and weight loss among those continuing cotrimoxazole. Collectively, these data highlight several previously unrecognized benefits of daily prophylaxis, despite high-level microbial resistance to cotrimoxazole in sub-Saharan Africa [6].

We previously reported reduced hospitalization for serious bacterial infections such as sepsis, meningitis, and pneumonia among children continuing cotrimoxazole [5]. The current study highlights additional benefits of cotrimoxazole for HIV-infected children on ART. Skin complaints are frequent, associated with stigma, and reduce quality of life [4]; they often necessitate clinic attendance and antibiotic prescriptions, and are associated with complications such as sepsis and poststreptococcal glomerulonephritis [11–13]. Skin infections remain common among HIV-infected children in sub-Saharan Africa despite ART [14]. In ARROW, one-third of children stopping cotrimoxazole developed bacterial skin infections during 2 years of follow-up; cotrimoxazole prophylaxis led to 64% lower odds of reported skin infections. Independent of cotrimoxazole, bacterial skin infections were more common in children aged 6–8 years and in those with more advanced HIV (CD4\(^+\) cell count <500 cells/μl and WHO stage 3/4 disease); consistent with this, longer duration of ART was associated with lower risk of bacterial skin infections. It is notable that there were consistent reductions in bacterial skin infections as assessed both by caregiver recall during nurse visits and on examination by physicians; by contrast, there were no reductions in viral or fungal infections, giving plausibility to our hypothesis that cotrimoxazole would prevent bacterial skin infections due to its antimicrobial spectrum of activity.

The global burden of bacterial skin infections has generally been underappreciated; a recent systematic review estimated that 162 million children are affected at any time by impetigo, predominantly in tropical, low-income countries [15]. In tropical regions, \( S. \) pyogenes is the predominant pathogen causing impetigo [9]; despite previous uncertainty, \( S. \) pyogenes is susceptible to cotrimoxazole in vivo [7]. A trial among indigenous Australian children with impetigo showed noninferiority of short-course oral cotrimoxazole compared with intramuscular benzathine benzylpenicillin for treatment [8]. There is increasing recognition that \( S. \) aureus is also an important cause of skin infections in tropical settings [10] and that \( S. \) pyogenes and \( S. \) aureus coinfection is common [9]. Published cotrimoxazole resistance rates among \( S. \) aureus isolates from sub-Saharan Africa are 25–100% [16–22], suggesting that cotrimoxazole has limited efficacy for staphylococcal skin infections; however, high intracellular concentrations may facilitate its antibacterial activity [23]. It has been noted in many previous studies that cotrimoxazole retains prophylactic activity against a range of infections despite high rates of resistance among causative organisms [5,24–27]. It is also plausible that the benefits of cotrimoxazole for skin infections are particularly driven by its activity against \( S. \) pyogenes [7]; there are few published data on cotrimoxazole resistance among \( S. \) pyogenes isolates in sub-Saharan Africa [6].

PPEs are one of the most frequent and troublesome skin complaints among HIV-infected individuals and can cause disfiguring and stigmatizing scarring [28–30]. The histopathology of PPE lesions is characterized by perivascular and interstitial lymphocytic and eosinophilic infiltration with epidermal hyperplasia, and likely arises from an exaggerated, Th2-skewed immune response to arthropod bites [30]. PPE has been related to higher viral loads [31,32] and to lower CD4\(^+\) cell counts in some [30,33] but not all [32,34] studies. We found a trend towards lower reports of PPE among children continuing cotrimoxazole, which is difficult to explain, but could plausibly be due to reduced frequency of impetiginized PPE lesions, immunomodulatory properties of cotrimoxazole [35–38], or miscategorization of PPE. Scabies frequently coexists with bacterial skin infections and, in this context, cotrimoxazole may have useful activity [39]; because scabies was not specifically diagnosed in this study, some cases of PPE may in fact have been due to underlying scabies with or without bacterial coinfection. In addition to our primary findings regarding skin complaints, children continuing cotrimoxazole were less likely to have caregiver-reported episodes of fever, weight loss, tiredness or weakness, bruises, poor appetite, nausea and cough, suggesting that cotrimoxazole has broader benefits than previously recognized [6]. Because cotrimoxazole is now recommended lifelong for HIV-infected children, it is likely to improve health and quality of life beyond the important reductions in mortality and hospitalization that underpinned the change in WHO guidance [40].
The main study strength is the randomization to continuing versus stopping cotrimoxazole, reducing bias from confounding, and the fact that children were enrolled across a range of ages. However, the main limitation is that the trial was open-label, so carers and clinicians knew whether children were receiving cotrimoxazole, which may have led to over-reporting of symptoms in those stopping. However, caregivers had been asked to recall this symptom list at every visit for 2 years prerandomization and for 2 years subsequently; because many symptoms were common, it would be hard to explain all effects as bias, particularly because only bacterial skin infections were reported significantly less frequently in those continuing. Furthermore, clinicians recorded bacterial skin infections (but not other skin complaints) less commonly on examination, corroborating caregiver reports. All events were diagnosed clinically; confirmatory microbiological and histopathological investigations were not available, which may have led to some misclassification of skin conditions. Longitudinal viral loads were not available in this study.

In summary, HIV-infected children continuing cotrimoxazole after ART-mediated immune reconstitution had fewer bacterial skin infections, which may reduce clinic attendances, prevent infectious and autoimmune complications, and improve quality of life. Together with reductions in other important signs and symptoms, such as cough, fever, weight loss, and PPEs, these findings highlight additional benefits to long-term cotrimoxazole prophylaxis in sub-Saharan Africa.

Acknowledgements

We thank the children, carers, and staff from all the centres participating in the ARROW trial. We thank Dr Asha Bowen for helpful discussions that led to this analysis.

Author contributions: Recruitment and data collection (M.B.-D., J.L., P.M., and A.K.), study supervision (M.J.T., A.S.W., and D.M.G.), data analysis (A.J.P. and A.S.W.), wrote first draft (A.J.P., A.S.W., and D.M.G.), critical revision of manuscript (M.B.-D., J.L., P.M., A.K., M.J.T., A.J.P., A.S.W., and D.M.G.).

Clinical and Trial Centres: MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda: P. Munderi, P. Nahiriya-Ntege, R. Kataramu, J. Lutaakome, F. Nankya, G. Nabulime, I. Sekamatte, J. Kyarimpa, A. Ruberantwari, R. Sebukyu, G. Tushabe, D. Wangi, L. Matama, M. Aber, M. Musinguzi, and D. Nakitto-Kesi.

Joint Clinical Research Centre, Kampala, Uganda: P. Mugyenyi, V. Musiime, R. Keishanyi, V.D. Afayo, J. Bwomezi, J. Byaruhanga, P. Erimu, C. Karungi, H. Kizito, W.S. Namala, J. Namusanje, R. Nandugwa, T.K. Najjuko, E. Natukunda, M. Ndigendawani, S.O. Nsilyona, R. Kibenge, B. Bainomuhwezi, D. Sseremba, J. Tezikyabbiri, C.S. Tumusiime, A. Balaba, A. Mugumya, F. Nghania, D. Mwebesa, M. Mutumba, E. Bagurukira, F. Odongo, S. Mubokyi, M. Ssenyonga, M. Kasango, E. Lutalo, and P. Orongo. University of Zimbabwe, Harare, Zimbabwe: K.J. Nathoo, M.F. Bwakura-Dangarembizi, F. Mapinge, E. Chidziva, T. Mhute, T. Vhembo, R. Mandiedwa, M. Chipiti, R. Dzapasi, C. Katanda, D. Nyoni, G.C. Tinago, J. Bhiri, S. Mudzingwa, D. Mucambaiwa, M. Phiri, V. Masore, C.C. Marozza, S.J. Maturure, S. Tsikirayi, L. Munetsi, K.M. Rashirai, J. Steamer, R. Nhema, W. Bikwa, T. Tambawoga, and E. Mufuka. Baylor College of Medicine Children's Foundation Uganda, Mulago Hospital Uganda: A. Kekitiinwa, P. Musoke, S. Bakeera-Kitaka, R. Namuddu, P. Kasirye, A. Babiri, J. Asello, S. Nakalanzu, N.C. Ssemambo, J. Nakafoero, J. Tikabamwe, G. Musoba, J. Ssanyu, and M. Kisekka. MRC Clinical Trials Unit, London, UK: D.M. Gibb, M.J. Thomason, A.S. Walker, A.D. Cook, B. Naidoo-James, M.J. Spyer, C. Male, A.J. Glabay, L.K. Kendall, J. Crawley, and A.J. Prendergast.

Independent ARROW Trial Monitors: I. Machigura and S. Ssenyonojo. Trial Steering Committee: I. Weller (Chair), E. Luyirika, H. Lyall, E. Mahanga, C. Mwansambbo, M. Nyathi, F. Miuro, D.M. Gibb, A. Kekitiinwa, P. Mugyenyi, P. Munderi, K.J. Nathoo; Observers S. Kinn, M. McNeil, M. Roberts, and W. Snowden. Data and Safety Monitoring Committee: A. Breckenridge (Chair), A. Pozniak, C. Hill, J. Matenga, J. Tumwine, and A.S. Walker. Endpoint Review Committee (independent members): G. Tudor-Williams (Chair), H. Barigye, H.A. Mujuru, and G. Ndeezi; (observers): S. Bakeera-Kitaka, M.F. Bwakura-Dangarembizi, J. Crawley, V. Musiime, P. Nahiriya-Ntege, A.J. Prendergast, and M. Spyer. ARROWN Immunology Group: N. Klein, B. Kampmann, A. Gomo, and G. Pimundu.

Funding: The current work was supported by the Medical Research Council (G0300400), Department for International Development and Wellcome Trust (grant number 108065/Z/15/Z to A.J.P.). ViiV Healthcare/ GlaxoSmithKline donated drugs and funded viral load assays.

Conflicts of interest

There are no conflicts of interest.

References

1. Mahe A, N’Diaye HT, Bobin P. The proportion of medical consultations motivated by skin diseases in the health centers of Bamako (Republic of Mali). Int J Dermatol 1997; 36:185–186.
Skin complaints in HIV-infected children Prendergast et al. 2829

2. Suleman M. Patterns of health-care utilization and morbidity in a rural community. Lahore, Pakistan. Ann Trop Med Parasitol 1996; 90:79–85.

3. World Health Organization. The current evidence for the burden of group A streptococcal diseases.WHO; 2005, http://www.who.int/maternal_child_adolescent/documents/skin-mucosal-and-hiv/en/. [Accessed on 11 March 2016].

4. World Health Organization. Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. -WHO; 2014, http://www.who.int/maternal_child_adolescent/documents/skin-mucosal-and-hiv/en/. [Accessed on 11 March 2016].

5. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahin-Ngote P, Keishanyu R, Nathok K, et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 2014; 370:41–53.

6. Church JA, Fitzgerald F, Walker AS, Gibb DM, Prendergast AJ. The expanding role of co-trimoxazole in developing countries. Lancet Infect Dis 2015; 15:327–339.

7. Bowen AC, Lillebridge RA, Tong SY, Baird RW, Ward P, McDonald ML, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole. J Clin Microbiol 2012; 50:4067–4072.

8. Bowen AC, Tong SY, Andrews RM, O’Meara IM, McDonald ML, Chatfield MD, et al. Short-term trials of oral co-trimoxazole versus intramuscular benzathine penicillin G for impetigo in a highly endemic region: an open-label, randomised, controlled, noninferiority trial. Lancet 2014; 384:2132–2140.

9. Bowen AC, Tong SY, Chatfield MD, Carapetis JR, Prendergast AJ. The microbiology of impetigo in indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus, scabies, and nasal carriage. BMC Infect Dis 2014; 14:722.

10. Tong SY, Steer AC, Jennings AW, Carapetis JR. Community-associated methicillin-resistant Staphylococcus aureus skin infections in the tropics. Dermatol Clin 2011; 29:21–32.

11. Carapetis JR, Steer AC, McMillan EL, Weber-M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685–694.

12. Carapetis JR, Walker AM, Hibble M, Sriprakash KS, Currie BJ. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS One 2015; 10:e0136789.

13. Marshall CS, Cheng AC, Markey PG, Fegan PK, et al. Antimicrobial susceptibilities of blood and nasopharyngeal isolates of group A streptococcal bacteria in New Zealand: a 10-year review. J Antimicrob Chemother 2015; 70:1167–1179.

14. Cotton MF, Wasserman E, Smijt J, Whelan L, Zar HJ. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis 2008; 8:40.

15. Madhi SA, Petersen K, Madhi A, Khosala M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 2000; 31:170–176.

16. Muszbek L, Smith JK, Akinfolade O, Bakeera-Kitaka S, Nahir-Ngote P, Keishanyu R, et al. Bacteremia, causative agents and antimicrobial susceptibility among HIV-infected children on antiretroviral therapy in Uganda and Zimbabwe. Pediatr Infect Dis J 2013; 32:835–862.

17. Chawla A, Kaur J, Prakash R, Kaur M, Kaur J. Antimicrobial resistance pattern of clinical isolates of Staphylococcus aureus in serum samples of HIV infected children. J Glob Infect Dis 2013; 5(3):153–157.

18. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulfamethoxazole for HIV-1-infected adults in Abidjan, Cote d’Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:463–466.

19. Chintu C, Bhat GI, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865–1871.

20. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428–1434.

21. Mwenya DM, Charafulamani BM, Phillips PP, Mwansa JC, Bittar SL, Nunn AJ. Impact of cotrimoxazole on carriage of antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob Agents Chemother 2010; 54:3756–3763.

22. Colebunders R, Mann JM, Francis H, Bila K, Izely, L, Kakonde N, et al. Generalized papular pururitic eruption in African patients with human immunodeficiency virus infection. AIDS 1987; 1:117–121.

23. Maruvda DR, Masenga EF, Brink M, Cramp JA, Bartlett JL. Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania. Int J Dermatol 2015; 54:68–73.

24. Resneck JS Jr, Van Beek M, Furmansi L, Ouyj, J LeBoit PE, Katabira E, et al. Etiology of purpuric papular eruption with HIV infection in Uganda. JAMA 2004; 292:2614–2621.

25. Castelnuovo B, Byakwaga H, Menten J, Schaefer P, Kamya M, Colebunders R. Can response of a purpuric papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome? AIDS 2008; 22:669–73.

26. Chua SL, Anderson EH, Leslie KS, McCallmont TH, Leboit PE, Martin JN, et al. Factors associated with purpuric papular eruption of human immunodeficiency virus infection in the antiretroviral therapy era. Br J Dermatol 2014; 170:832–839.

27. Farsiati T, Kore S, Nadiro P, Mann M, Therian SL, Leslie K, et al. Etiology and risk factors associated with a purpuric papular eruption in people living with HIV in India. Int J AIDS Soc 2013; 16:17325.

28. Navarini AA, Stoeckle M, Navarini S, Mosdorf E, Julla BS, McHomvu R, et al. Antihistamines are superior to topical steroids in managing human immunodeficiency virus (HIV)-associated papular purpuric eruption. J Am Acad Dermatol 2010; 62:381–390.

29. Anderson KR, Grabow G, Olsuizen R, Theron A, Van Rensburg AJ. Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: in vivo effects of co-trimoxazole. Antimicrob Agents Chemother 1980; 17:322–326.

30. Dubar V, Lopez I, Gossel-P, Aerts C, Voisin C, Wallaert B. The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. J Infect Microbiol Chemother 1993; 26:791–802.

31. Gaylarde PM, Sarkany I. Suppression of thrombocytopenia of human lymphocytes by co-trimoxazole. Br Med J 1972; 3:144–146.

32. Ghilchik MW, Morris AS, Reeves DS. Immunosuppressive powers of the antibacterial agent trimethoprim. Nature 1970; 227:393–394.

33. Tanasi M, Tong SY, Andrews RM, Holt DC, Currie BJ, Carapetis JR, et al. The importance of scabies coinfection in the treatment considerations for impetigo. Pediatr Infect Dis J 2016; 35:374–378.

34. World Health Organization. Guidelines on postexposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children. Recommendations for a public health approach – December 2014 supplement to the 2013 consolidated ARV guidelines.WHO; 2014, http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013supplement_dec2014/en/. [Accessed on 11 March 2016].

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.